Interferons and interferon inhibitory activity in disease and therapy

被引:12
作者
Chadha, KC
Ambrus, JL
Dembinski, W
Ambrus, JL
机构
[1] SUNY Buffalo, Buffalo Gen Hosp, Kaleida Hlth Syst, Dept Internal Med, Buffalo, NY 14203 USA
[2] SUNY Buffalo, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14203 USA
关键词
interferon inhibitors; alpha/beta type 1 interferon receptors; pathophysiology of neoplastic diseases; viral infections; AIDS; autoimmune diseases;
D O I
10.1177/153537020422900402
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Interferon (IFN) resistance is an important factor in the pathophysiology of neoplastic disorders, certain viral infections (e.g., AIDS), and autoimmune diseases (e.g., lupus erythematosus and Wegner's granulomatosis). In addition, in some of these disorders, there is also decreased ability to produce IFNs. The capacity of viruses and neoplastic processes to interfere with the IFN system are thought to represent a "virus-against-host" or "cancer-against-host" defense mechanism. Four resistance factors have been identified: 1) release of free IFN-alpha/beta type 1 receptors into the circulation that, at appropriate concentrations, capture and inactivate IFNs; 2) a new IFN inhibitory protein has been isolated and its chemical structure is under study; 3) prostaglandin E-2, which is produced by certain tumor cells, inhibits IFN production; and 4) high levels of cAMP phosphodiesterases present, for example in certain tumor cells, reduces cAMP, an important second messenger in IFN synthesis. Studies are under way to reverse these inhibitory effects and to increase endogenous interferon production.
引用
收藏
页码:285 / 290
页数:6
相关论文
共 50 条
  • [1] AMBRUS JL, 1992, RES COMMUN CHEM PATH, V78, P249
  • [2] INTERFERON INHIBITORS
    AMBRUS, JL
    CHADHA, KC
    AMBRUS, JL
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 114 (07) : 606 - 607
  • [3] AMBRUS JL, 1993, SURG GYNECOL OBSTET, V176, P588
  • [4] AMBRUS JL, 1989, AM J MED, V87, P405, DOI 10.1016/S0002-9343(89)80822-8
  • [5] Ambrus JL, 1997, RES COMMUN MOL PATH, V96, P255
  • [6] AMBRUS JL, 1999, P SPRING CLIN DAY ST, P1
  • [7] AMBRUS JL, 2004, CANCER, V98, P2730
  • [8] AMBRUS JL, 1986, NEW ENGL J MED, V319, P582
  • [9] ASZALOS A, 1991, J MED, V22, P255
  • [10] ATTALLAH A, 1984, RES COMMUN CHEM PATH, V43, P195